Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002852 | 0.88 | LMNA (0.50) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL21693932 | 0.86 | CES2 (0.49) | LMNATSHRTDP1CES2CES1 | |
| SCHEMBL332835 | 0.85 | LMNA (0.53) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL20503264 | 0.82 | LMNA (0.51) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL20503355 | 0.82 | LMNA (0.51) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL27343099 | 0.79 | LMNA (0.52) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL7934395 | 0.76 | LMNA (0.49) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL7934397 | 0.76 | LMNA (0.49) | LMNATSHRF2TDP1CES2 | |
| SCHEMBL9667200 | 0.76 | LMNA (0.49) | LMNATSHRF2TDP1CES2 | |
| Alcohol SCHEMBL28171595 | 0.76 | LMNA (0.52) | LMNATSHRF2TDP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9074021-B2 | Cellulose derivative, thermo-molding material, molded body and method for preparation thereof, and case for electric and electronic devices | FUJIFILM CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2465899-B1 | CELLULOSE DERIVATIVE, THERMOFORMED MATERIAL, MOLDED BODY, PRODUCTION METHOD THEREFOR, AND CASING FOR ELECTRICAL AND ELECTRONIC EQUIPMENT | FUJIFILM CORP (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-20120165517-A1 | CELLULOSE DERIVATIVE, THERMO-MOLDING MATERIAL, MOLDED BODY AND METHOD FOR PREPARATION THEREOF, AND CASE FOR ELECTRIC AND ELECTRONIC DEVICES | FUJIFILM CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2465899-A1 | CELLULOSE DERIVATIVE, THERMOFORMED MATERIAL, MOLDED BODY, PRODUCTION METHOD THEREFOR, AND CASING FOR ELECTRICAL AND ELECTRONIC EQUIPMENT | FUJIFILM Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2005040095-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
| US-5466691-A | Antipsychotic and anxiolytic agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0601184-A1 | FUSED PYRIDAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0596120-A1 | THIOPHENE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0236074-B1 | 2BETA-SUBSTITUTED THIOMETHYLPENICILLIN DERIVATIVES AND THEIR PREPARATION AND USE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0049539-B1 | THIAZOLE DERIVATIVES FOR PREPARING CEPHEM COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-16 | — | — | EP | disclosed |
| US-4529592-A | Substituted in position 2 with a (4,5-diester-1,2,3-triazol-3-yl)alkyl group | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | disclosed |
| EP-0007633-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-04-18 | — | — | EP | disclosed |
| US-4372952-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0049539-A1 | Thiazole derivatives for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-04-14 | — | — | EP | disclosed |
| US-4284631-A | 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| EP-0007633-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | disclosed |
| US-4179435-A | SULPHONIC ACID-FREE | CIBA-GEIGY CORPORATION (US) | 1979-12-18 | — | — | US | disclosed |
| US-4115381-A | FOR POLYESTER FIBERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | LMNA 2544/4885TSHR 2112/4885F2 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.